Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Accumulated Expenses (2023 - 2025)

Neurogene's Accumulated Expenses history spans 3 years, with the latest figure at $10.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 10.53% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, up 10.53%, while the annual FY2025 figure was $10.8 million, 10.53% up from the prior year.
  • Accumulated Expenses reached $10.8 million in Q4 2025 per NGNE's latest filing, up from $9.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $17.5 million in Q4 2023 to a low of $6.8 million in Q1 2024.
  • Average Accumulated Expenses over 3 years is $9.8 million, with a median of $9.4 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: crashed 44.38% in 2024, then grew 27.34% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $17.5 million in 2023, then plummeted by 44.38% to $9.7 million in 2024, then rose by 10.53% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Accumulated Expenses are $10.8 million (Q4 2025), $9.4 million (Q3 2025), and $9.1 million (Q2 2025).